Vireo Growth (OTCPK:VREOF) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Vireo Growth Forward PE Ratio Related Terms
Vireo Growth Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Vireo Growth's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vireo Growth Forward PE Ratio Chart
Vireo Growth Annual Data
Trend
2021-12
2025-12
Forward PE Ratio
11.75
9.91
Vireo Growth Quarterly Data
2021-09
2021-12
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
12.97
11.75
42.50
7.54
9.91
7.43
VREOF vs ZTS, UTHR: Forward PE Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vireo Growth's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vireo Growth Forward PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vireo Growth's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Vireo Growth's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Vireo Growth (VREOF) has a Forward PE Ratio of 59.21 as of Jul. 08, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Vireo Growth and its competitors. According to the industry distribution chart, Vireo Growth ranks #317 out of 408 companies in the Drug Manufacturers industry, placing it in the top 77.7%.
Is Vireo Growth's Forward PE Ratio too high?
Vireo Growth's current Forward PE Ratio is 59.21. The Drug Manufacturers industry median Forward PE Ratio is 17.36. Vireo Growth's value of 59.21 is 241.1% above this industry median. Based on the distribution chart, Vireo Growth ranks #317 out of 408 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vireo Growth has a GF Score™ of 46/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vireo Growth's Forward PE Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vireo Growth ranks #317 out of 408 companies for Forward PE Ratio. This places Vireo Growth in the lower half of its industry. The industry median Forward PE Ratio is 17.36. Vireo Growth's value of 59.21 is 241.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Drug Manufacturers company?
The median Forward PE Ratio among Drug Manufacturers companies is 17.36, based on 408 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vireo Growth's current Forward PE Ratio of 59.21 is 241.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Vireo Growth and its competitors. For the Drug Manufacturers industry, the median Forward PE Ratio is 17.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vireo Growth's current Forward PE Ratio is 59.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vireo Growth stock overvalued right now?
Based on GuruFocus' analysis, Vireo Growth (VREOF) is currently considered Fairly Valued. The stock's GF Value™ is $9.69, compared to a current price of $10.07 — trading 3.9% above its estimated fair value. The current Forward PE Ratio is 59.21 and 241.1% above the Drug Manufacturers industry median of 17.36. Vireo Growth's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Vireo Growth (VREOF), the current Forward PE Ratio is 59.21 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vireo Growth (VREOF) Overvalued in 2026?
Based on GuruFocus' analysis, Vireo Growth stock appears to be overvalued.
The current stock price of $10.07 is trading 3.9% above its estimated GF Value™ of $9.69.
GuruFocus considers Vireo Growth to be Fairly Valued.
Key valuation signals for VREOF:
Forward PE Ratio: 59.21
GF Value™: $9.69 vs. price of $10.07 (3.9% above fair value)
Industry Position: 241.1% above the Drug Manufacturers median (#317 of 408)
No single metric tells the full story. See the VREOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vireo Growth Incis a cannabis company whose mission is to provide safe access, quality products and value to its customers while supporting its local communities through active participation and restorative justice programs. The Company is evolving with the industry and is in the midst of a transformation to being significantly more customer-centric across its operations, which include cultivation, manufacturing, wholesale and retail business lines. The company operates in one single segment.
46GF Score
Get the complete analysis for VREOF
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VREOF has been successfully added to your 